Ptc Therapeutics (PTCT) Stock Price, Quote & News

Company Profile

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spi...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 222 7000

Website: www.ptcbio.com

Address:

500 Warren Corporate Center Drive, Warren, United States

Doozio Jul. 3 at 4:04 PM

$PTCT $IONS huckleberries n YUGE $$$$ patterns. faaatch 💣 or 🌙 ENTA 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jul. 3 at 3:01 PM

$PTCT chop chop huckleberries ENTA 🐒🍌🧠⏰♾️

1 · Reply

Quantumup Jul. 2 at 1:26 PM

H.C. Wainwright assumed coverage on $LRMR Buy-$10—forecast a commercial launch of nomlabofusp in 2027 with sales of $47.9M that year, growing to peak annual sales of >$1.1B by 2040E. $PTCT $LXEO SLDB BIIB DSGN Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2072672948868034938?s=20

0 · Reply

JasonCO Jun. 17 at 3:31 PM

$PTCT gimme hundo

0 · Reply

SwingTraderPro1 Jun. 17 at 2:29 PM

PREMARKET MOVERS - JUNE 17 SPACE / NEXT-GEN INFRASTRUCTURE • $ASTS +5% — rising after successful BlueBird 8–10 satellite deployment via SpaceX Falcon 9, reinforcing space-based connectivity rollout narrative ENERGY / STORAGE • $EOSE +6% — momentum building after commercial production start at Battery Line 2 (Thorn Hill) plus visibility into multi-GWh storage pipeline and agreements FINTECH / RETAIL FLOW • $HOOD +2% — modest strength alongside retail trading and crypto-linked sentiment support BIOTECH • $PBLS +10% — standout early biotech mover with strong premarket volume expansion • $PTCT +5% — continuing relative strength within higher-beta biotech group Theme today: capital rotation into high-beta infrastructure + event-driven names across space, storage, and biotech while broader risk appetite remains constructive.

0 · Reply

dgbio Jun. 17 at 1:52 PM

$PTCT If QURE can file on Phase 2 data, PTC with Novartis should be able to do the same.

0 · Reply

dgbio Jun. 16 at 6:11 AM

$PTCT Nice terms on covertible: zero coupon, 107.48 conversion price

0 · Reply

G101SPM Jun. 15 at 12:57 PM

#DILUTION Freedom Holding Corp. ($FRHC) launches common stock offering Pattern Group ($PTRN) announces the launch of a public offering of 8,000,000 shares of Series A common stock to be sold by an entity affiliated with Knox Lane LP, a pre-IPO stockholder of Pattern PTC Therapeutics ($PTCT) intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2031 in a private placement Venu Holding Corp. ($VENU) discloses that it entered into an ATM sales agreement; may offer up to $250 mln of common stock

0 · Reply

anachartanalyst Jun. 9 at 8:01 PM

$PTCT https://anachart.com/wp-content/uploads/2026/06/1781035292_soc-img.jpg

0 · Reply

notreload_ai Jun. 9 at 12:40 PM

Citi turns bullish on $PTCT, citing strong Sephience sales in PKU and potential $1B+ peak, raising target to $108. https://notreload.xyz/xy/sephience-sales-momentum-prompts-citi-to-upgrade-ptct-to-buy/

0 · Reply

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 15, 2026, 11:14 PM EDT - 18 days ago

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

PTC

2026-06-15T11:21:26.000Z - 19 days ago

PTC Therapeutics files to sell $500M of Convertible Senior Notes due 2031

Jun 15, 2026, 7:00 AM EDT - 19 days ago

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

PTC

Jun 9, 2026, 9:20 AM EDT - 25 days ago

PTC Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-09T09:50:09.000Z - 25 days ago

PTC Therapeutics assumed with Buy from Neutral at Citi

Jun 2, 2026, 9:00 AM EDT - 4 weeks ago

PTC Therapeutics Transcript: AGM 2026

2026-05-27T13:16:50.000Z - 5 weeks ago

PTC Therapeutics upgraded to Buy from Hold at Jefferies

May 20, 2026, 10:00 AM EDT - 6 weeks ago

PTC Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 12, 2026, 11:40 AM EDT - 7 weeks ago

PTC Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-11T12:44:54.000Z - 7 weeks ago

PTC Therapeutics price target raised to $89 from $80 at JPMorgan

May 10, 2026, 10:15 AM EDT - 7 weeks ago

PTC Therapeutics Slides: Corporate presentation

2026-05-08T14:23:32.000Z - 2 months ago

PTC Therapeutics price target raised to $94 from $92 at Morgan Stanley

2026-05-08T09:30:23.000Z - 2 months ago

PTC Therapeutics upgraded to Buy from Hold at TD Cowen

2026-05-07T21:40:07.000Z - 2 months ago

PTC Therapeutics reports Q1 EPS (3c) vs. ($10.04) last year

2026-05-07T21:38:12.000Z - 2 months ago

PTC Therapeutics raises 2026 revenue view to $1.08B-$1.18B, consensus $990.78M

May 7, 2026, 4:30 PM EDT - 2 months ago

PTC Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

PTC Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

PTC Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:01 PM EDT - 2 months ago

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 4, 2026, 8:00 AM EDT - 2 months ago

PTC Therapeutics to Participate in Upcoming Investor Conferences

Apr 28, 2026, 4:30 PM EDT - 2 months ago

PTC Therapeutics Transcript: Study result

Apr 28, 2026, 4:30 PM EDT - 2 months ago

PTC Therapeutics Press release: Study result

Apr 28, 2026, 4:30 PM EDT - 2 months ago

PTC Therapeutics Slides: Study result

2026-04-28T20:26:21.000Z - 2 months ago

PTC Therapeutics reports ‘positive’ results from PIVOT-HD study

Apr 28, 2026, 4:05 PM EDT - 2 months ago

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

Apr 28, 2026, 9:28 AM EDT - 2 months ago

PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study

Apr 22, 2026, 8:00 AM EDT - 2 months ago

PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026

Apr 20, 2026, 8:00 AM EDT - 2 months ago

PTC Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

PTC Therapeutics Proxy statement: Proxy filing

2026-04-10T09:40:30.000Z - 3 months ago

PTC Therapeutics initiated with an Outperform at Raymond James

2026-04-09T20:37:54.000Z - 3 months ago

PTC Therapeutics initiated with an Outperform at Raymond James

2026-04-07T15:09:48.000Z - 3 months ago

PTC Therapeutics price target lowered to $81 from $82 at RBC Capital

Mar 25, 2026, 8:30 AM EDT - 3 months ago

PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

Mar 11, 2026, 8:00 AM EDT - 4 months ago

PTC Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 4:20 PM EDT - 4 months ago

PTC Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 9:50 AM EST - 4 months ago

PTC Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 8:00 AM EST - 4 months ago

PTC Therapeutics to Participate at Upcoming Investor Conferences

Feb 19, 2026, 4:30 PM EST - 4 months ago

PTC Therapeutics Earnings Call Transcript: Q4 2025

Feb 19, 2026, 4:30 PM EST - 4 months ago

PTC Therapeutics Annual report: Q4 2025

Feb 19, 2026, 4:30 PM EST - 4 months ago

PTC Therapeutics Earnings release: Q4 2025

Feb 19, 2026, 4:30 PM EST - 4 months ago

PTC Therapeutics Annual report: Q4 2025

Feb 19, 2026, 4:01 PM EST - 4 months ago

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 19, 2026, 7:00 AM EST - 4 months ago

PTC Therapeutics Slides: Corporate presentation

Feb 12, 2026, 5:00 PM EST - 5 months ago

PTC Therapeutics Provides Regulatory Update on Translarna™

Feb 5, 2026, 8:00 AM EST - 5 months ago

PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

Jan 12, 2026, 12:00 PM EST - 6 months ago

PTC Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:00 PM EST - 6 months ago

PTC Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:30 AM EST - 6 months ago

PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference

Dec 22, 2025, 7:00 AM EST - 6 months ago

PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan

Dec 18, 2025, 8:00 AM EST - 7 months ago

PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 4, 2025, 10:30 AM EST - 7 months ago

PTC Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 9:30 AM EST - 7 months ago

PTC Therapeutics Transcript: R&D Day 2025

Dec 2, 2025, 9:30 AM EST - 7 months ago

PTC Therapeutics Slides: FY 2025

Dec 1, 2025, 9:00 AM EST - 7 months ago

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

CVKD

Nov 24, 2025, 6:01 PM EST - 7 months ago

Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600

FIBK GIL HBI IPG OMC PINC SNDK

Nov 20, 2025, 8:00 AM EST - 8 months ago

PTC Therapeutics to Host R&D Day

Nov 18, 2025, 3:00 AM EST - 8 months ago

PTC Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 3:30 PM EST - 8 months ago

PTC Therapeutics Transcript: UBS Global Healthcare Conference 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

PTC Therapeutics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

PTC Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

PTC Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 8 months ago

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:00 PM EST - 8 months ago

PTC Therapeutics Slides: Corporate Presentation

Oct 21, 2025, 8:00 AM EDT - 9 months ago

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results

Sep 8, 2025, 9:15 AM EDT - 10 months ago

PTC Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 11:00 AM EDT - 10 months ago

PTC Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 8:35 AM EDT - 10 months ago

PTC Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 19, 2025, 8:06 AM EDT - 11 months ago

US FDA declines to approve PTC Therapeutics' rare genetic disorder drug

Aug 19, 2025, 8:00 AM EDT - 11 months ago

PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA

Aug 7, 2025, 4:30 PM EDT - 11 months ago

PTC Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

PTC Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

PTC Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:01 PM EDT - 11 months ago

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 28, 2025, 5:00 PM EDT - 1 year ago

PTC Therapeutics Transcript: Study Update

Jul 28, 2025, 5:00 PM EDT - 1 year ago

PTC Therapeutics Press release: Study Update

Jul 28, 2025, 4:25 PM EDT - 1 year ago

US FDA approves PTC Therapeutics' metabolic disorder drug

Jul 28, 2025, 4:19 PM EDT - 1 year ago

PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

Jul 21, 2025, 4:30 PM EDT - 1 year ago

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

Doozio Jul. 3 at 4:04 PM

$PTCT $IONS huckleberries n YUGE $$$$ patterns. faaatch 💣 or 🌙 ENTA 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jul. 3 at 3:01 PM

$PTCT chop chop huckleberries ENTA 🐒🍌🧠⏰♾️

1 · Reply

Quantumup Jul. 2 at 1:26 PM

0 · Reply

JasonCO Jun. 17 at 3:31 PM

$PTCT gimme hundo

0 · Reply

SwingTraderPro1 Jun. 17 at 2:29 PM

0 · Reply

dgbio Jun. 17 at 1:52 PM

$PTCT If QURE can file on Phase 2 data, PTC with Novartis should be able to do the same.

0 · Reply

dgbio Jun. 16 at 6:11 AM

$PTCT Nice terms on covertible: zero coupon, 107.48 conversion price

0 · Reply

G101SPM Jun. 15 at 12:57 PM

0 · Reply

anachartanalyst Jun. 9 at 8:01 PM

$PTCT https://anachart.com/wp-content/uploads/2026/06/1781035292_soc-img.jpg

0 · Reply

notreload_ai Jun. 9 at 12:40 PM

0 · Reply

Night_Owl_Biotech Jun. 9 at 2:17 AM

$ACAD versus $PTCT & $NBIX (all 3 had their first FDA approval 2016 - 2017. We even noted FY25 SG&A (excluding noncash compensation). Yes ACAD is $200MM higher than PTCT but... I do not know how to make it any simpler. Should ACAD merit a peer revenue multiple ACAD would trade 50% higher? Eventually ACAD's BOD must do something to maximize shareholder value (hopefully just like APLS). This is not investment advice. $XBI $IBB

0 · Reply

Thelonius_Stonk Jun. 4 at 5:03 PM

$PTCT thoon

1 · Reply

codename41 May. 29 at 1:50 PM

$PTCT load

0 · Reply

Ak4777 May. 28 at 2:45 PM

$PTCT 💎

0 · Reply

Thelonius_Stonk May. 27 at 7:58 PM

$PTCT the beast waking up

0 · Reply

Quantumup May. 27 at 10:40 AM

JPMorgan🏁 $LRMR and said: We are initiating coverage of Larimar Therapeutics (LRMR) with an Overweight rating and a Dec 2027 price target of $9. $PTCT SLDB BIIB DSGN $LXEO Larimar's lead asset is nomlabofusp (nomla; CTI-1601), a subcutaneously administered, recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare neurodegenerative disorder. In the near-term, in 2Q26, we expect to see topline results from the ongoing open-label (OL) study as well as feedback from the company's type B meeting with the FDA to align on the overall BLA package readiness. The company expects a rolling BLA submission for accelerated approval (AA) in June 2026, pending FDA feedback, using skin FXN levels as a surrogate endpoint, with the final submission including the CMC module expected in 2H26; if approved, nomla would be the first FXN replacement therapy for FA, with a potential U.S. approval and launch in 1H27.

0 · Reply

JasonCO May. 20 at 1:43 PM

$PTCT how the hell did I get filled at $62.83 this morning? Whatever

0 · Reply

NVDAMillionaire May. 19 at 9:54 PM

$PTCT Outstanding article that hits the mark on PTCT's current state. So if you want to refresh your PTCT insights or learn about PTCT from scratch, this is a must read. https://everyticker.com/quote/PTCT/analysis/sephience-s-blockbuster-launch-and-strategic-clarity-redefine-ptc-therapeutics-path-to-profitability-nasdaq-ptct

1 · Reply

SanKish May. 17 at 10:45 PM

$ACAD $LQDA $PTCT $XBI both of you should get on the board. Some of us have been holding because of the potential but it has been few years now. Either the company executes the growth model or sells the potential to a buyer. Thanks for sharing your detailed analysis. I am not sure though if there will be much of a change by fall as there can be a market driven downturn by then.

0 · Reply

outlawinvestor1 May. 17 at 6:51 PM

$ACAD $PTCT $XBI nice work. unbelievable value on the table for acadia imho, given the analysis below doesn't even include pipeline pys opportunity. including $LQDA as well.

1 · Reply

Night_Owl_Biotech May. 17 at 6:05 PM

Analysts project $ACAD to generate slightly more revenues than $PTCT over the next 5 & 10 years. Both ACAD & PTCT have historic gross margin profiles in the low nineties. Actual FY2025 gross margin for both was 92%. Even though analysts project ACAD to generate more revenues than PTCT at the same gross margin profile, ACAD's market cap is roughly 60% of PTCT's market cap. Because PTCT's capital structure includes meaningful term debt, PTCT's enterprise value is about 150% higher than ACAD. The attachment graphs analyst consensus of both over the next 10 years. Both had their 1st FDA approval 9 years ago. Reading the graph knowing both generate the same gross margin, does it seem logical PTCT's enterprise value is 150% higher than ACAD? We're not bashing PTCT. This is not investment advice. Rather, we're genuinely trying to understand the disconnect in valuation. $XBI $IBB $IBBQ

0 · Reply

Quantumup May. 13 at 12:50 PM

BRiley reiterated $CAPR Buy; $63 $EWTX DYN SLDB SRPT $PTCT Here's what BRiley said in its note to investors: https://x.com/Quantumup1/status/2054543899402596420?s=20

0 · Reply

Market Cap	6.91B
Revenue (ttm)	1.73B
Net Income (ttm)	682.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	103.76
Profit Margin	39.44%
Debt to Equity Ratio	-14.49

Volume	6,778,000
Avg Vol	1,912,552
Day's Range	N/A - N/A
Shares Out	82.95M
Stochastic %K	51%
Beta	0.53
Analysts	Strong Sell
Price Target	$93.93